Selected article for: "EBOV replicon and RNA interference"
Author: Shu, Ting; Gan, Tianyu; Bai, Peng; Wang, Xiaotong; Qian, Qi; Zhou, Hui; Cheng, Qi; Qiu, Yang; Yin, Lei; Zhong, Jin; Zhou, Xi
Title: Ebola virus VP35 has novel NTPase and helicase-like activities
  • Document date: 2019_6_20
    • ID: u3pxycqh_59
    Snippet: Of note, the minigenome replication/transcription seemed be more sensitive to GuHCl treatment than the biochemical activities of VP35. It is possible that because EBOV minigenomic RNA replication is a multi-round process, a slight inhibition in each round can result in an accumulated effect. Besides, when comparing with transiently transfected minigenome system, this stable EBOV minigenome replicon has been reported to show high level of active m.....
    Document: Of note, the minigenome replication/transcription seemed be more sensitive to GuHCl treatment than the biochemical activities of VP35. It is possible that because EBOV minigenomic RNA replication is a multi-round process, a slight inhibition in each round can result in an accumulated effect. Besides, when comparing with transiently transfected minigenome system, this stable EBOV minigenome replicon has been reported to show high level of active minigenome replication, and be relatively stable and even insensitive to IFN treatment or RNA interference, probably due to the persistent replication and the strong viral RNP stability of this minigenome (41) . Therefore, the inhibitory effect of GuHCl on the replication and transcription of EBOV minigenome is quite remarkable. In conclusion, our results show that GuHCl is able to inhibit the replication and transcription of the EBOV minigenome replicon in cultured human cells at the concentrations without apparent cytotoxicity.

    Search related documents:
    Co phrase search for related documents
    • high level and IFN treatment: 1, 2, 3, 4
    • high level and inhibitory effect: 1, 2, 3, 4, 5, 6, 7
    • high level and minigenome replication: 1
    • high level and minigenome system: 1
    • high level and persistent replication: 1
    • high level and replication transcription: 1, 2, 3, 4
    • high level and RNA interference: 1, 2, 3
    • high level and transcription replication: 1, 2, 3, 4
    • human cell and IFN treatment: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19
    • human cell and inhibitory effect: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37
    • human cell and persistent replication: 1, 2
    • human cell and replication transcription: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
    • human cell and RNA interference: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17
    • human cell and transcription replication: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
    • IFN treatment and inhibitory effect: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
    • IFN treatment and persistent replication: 1
    • IFN treatment and replication transcription: 1, 2, 3
    • IFN treatment and transcription replication: 1, 2, 3
    • inhibitory effect and minigenome replication: 1